153 related articles for article (PubMed ID: 36714174)
1. Treatment preferences in relation to fatigue of patients with relapsing multiple sclerosis: A discrete choice experiment.
Tervonen T; Fox RJ; Brooks A; Sidorenko T; Boyanova N; Levitan B; Hennessy B; Phillips-Beyer A
Mult Scler J Exp Transl Clin; 2023; 9(1):20552173221150370. PubMed ID: 36714174
[TBL] [Abstract][Full Text] [Related]
2. The relevance of fatigue to relapse rate in multiple sclerosis: Applying patient preference data to the OPTIMUM trial.
Fox RJ; Tervonen T; Phillips-Beyer A; Sidorenko T; Boyanova N; Brooks A; Hennessy B; Jamieson C; Levitan B
Mult Scler; 2023 Mar; 29(3):427-435. PubMed ID: 36550636
[TBL] [Abstract][Full Text] [Related]
3. Real-world treatment preferences among health care providers in the United States in selecting disease modifying therapies for patients with multiple sclerosis: a discrete choice experiment.
Bandari D; Adamson M; Bowman M; Gutierrez A; Athavale A; Oak B; Hadker N; Branco F; Geremakis C; Lewin JB; Shankar SL
J Med Econ; 2023; 26(1):1507-1518. PubMed ID: 37934412
[TBL] [Abstract][Full Text] [Related]
4. Patient preferences for treatment of multiple sclerosis with disease-modifying therapies: a discrete choice experiment.
Garcia-Dominguez JM; Muñoz D; Comellas M; Gonzalbo I; Lizán L; Polanco Sánchez C
Patient Prefer Adherence; 2016; 10():1945-1956. PubMed ID: 27713622
[TBL] [Abstract][Full Text] [Related]
5. The Impact of Reproductive Issues on Preferences of Women with Relapsing Multiple Sclerosis for Disease-Modifying Treatments.
Webb EJD; Meads D; Eskytė I; Ford HL; Bekker HL; Chataway J; Pepper G; Marti J; Okan Y; Pavitt SH; Schmierer K; Manzano A
Patient; 2020 Oct; 13(5):583-597. PubMed ID: 32588337
[TBL] [Abstract][Full Text] [Related]
6. Preferences of patients for benefits and risks of insomnia medications using data elicited during two phase III clinical trials.
Heidenreich S; Ross M; Chua GN; Seboek Kinter D; Phillips-Beyer A
Sleep; 2022 Nov; 45(11):. PubMed ID: 36054921
[TBL] [Abstract][Full Text] [Related]
7. Patients' Preferences for Systemic Lupus Erythematosus Treatments-A Discrete Choice Experiment.
Collacott H; Phillips-Beyer A; Krucien N; Flamion B; Marsh K
Patient; 2024 May; 17(3):287-300. PubMed ID: 38270788
[TBL] [Abstract][Full Text] [Related]
8. Current Health State Affected Patient Preferences More Than Disease Status: A Discrete Choice Experiment in Multiple Myeloma.
Tervonen T; Duenas A; Collacott H; Lam A; Gries KS; Carson R; Trevor N; Krucien N; He J
Value Health; 2023 Jun; 26(6):909-917. PubMed ID: 36738785
[TBL] [Abstract][Full Text] [Related]
9. Treatment preferences of patients with relapsed or refractory multiple myeloma in the United States, United Kingdom, Italy, Germany, France, and Spain: results from a discrete choice experiment.
Thomas C; Ailawadhi S; Popat R; Kleinman D; Ross MM; Gorsh B; Mulnick S; O'Neill A; Paka P; Hanna M; Krucien N; Molinari A; Gelhorn HL; Perera S
Front Med (Lausanne); 2023; 10():1271657. PubMed ID: 38076274
[TBL] [Abstract][Full Text] [Related]
10. A discrete-choice experiment to determine patient preferences for injectable multiple sclerosis treatments in Germany.
Poulos C; Kinter E; Yang JC; Bridges JF; Posner J; Gleißner E; Mühlbacher A; Kieseier B
Ther Adv Neurol Disord; 2016 Mar; 9(2):95-104. PubMed ID: 27006697
[TBL] [Abstract][Full Text] [Related]
11. An international discrete choice experiment assessing patients' preferences for disease-modifying therapy attributes in multiple sclerosis.
Bauer B; Brockmeier B; Devonshire V; Charbonne A; Wach D; Hendin B
Neurodegener Dis Manag; 2020 Dec; 10(6):369-382. PubMed ID: 32873160
[No Abstract] [Full Text] [Related]
12. An implantable device to treat multiple sclerosis: A discrete choice experiment on patient preferences in three European countries.
Visser LA; Huls SPI; Uyl-de Groot CA; de Bekker-Grob EW; Redekop WK
J Neurol Sci; 2021 Sep; 428():117587. PubMed ID: 34364148
[TBL] [Abstract][Full Text] [Related]
13. PREFERENCES OF PATIENTS WITH MULTIPLE SCLEROSIS FOR ATTRIBUTES OF INJECTABLE MULTIPLE SCLEROSIS TREATMENTS IN THE UNITED KINGDOM AND FRANCE.
Poulos C; Kinter E; van Beek J; Christensen K; Posner J
Int J Technol Assess Health Care; 2018 Jan; 34(4):425-433. PubMed ID: 30251947
[TBL] [Abstract][Full Text] [Related]
14. Patients' preferences and willingness-to-pay for disease-modifying therapies.
Frost N; Freeman J; Brixner D; Mort J; Clem J; Ngorsuraches S
Mult Scler Relat Disord; 2019 Oct; 35():55-60. PubMed ID: 31323483
[TBL] [Abstract][Full Text] [Related]
15. A discrete choice experiment to determine patient preferences for injection devices in multiple sclerosis.
Shingler SL; Swinburn P; Ali S; Perard R; Lloyd AJ
J Med Econ; 2013 Aug; 16(8):1036-42. PubMed ID: 23730944
[TBL] [Abstract][Full Text] [Related]
16. Patient Preferences for Injectable Treatments for Multiple Sclerosis in the United States: A Discrete-Choice Experiment.
Poulos C; Kinter E; Yang JC; Bridges JF; Posner J; Reder AT
Patient; 2016 Apr; 9(2):171-80. PubMed ID: 26259849
[TBL] [Abstract][Full Text] [Related]
17. A discrete choice experiment to determine UK patient preference for attributes of disease modifying treatments in Multiple Sclerosis.
Bottomley C; Lloyd A; Bennett G; Adlard N
J Med Econ; 2017 Aug; 20(8):863-870. PubMed ID: 28562125
[TBL] [Abstract][Full Text] [Related]
18. Patient and neurologist preferences in the UK for relapsing-remitting multiple sclerosis treatments: findings from a discrete choice experiment.
Tencer T; Will O; Kumar J; Cambron-Mellott MJ; Mackie DS; Beusterien K
Curr Med Res Opin; 2021 Sep; 37(9):1589-1598. PubMed ID: 34129418
[TBL] [Abstract][Full Text] [Related]
19. Modeling the impact of patient treatment preference on health outcomes in relapsing-remitting multiple sclerosis.
van Eijndhoven E; Brauer M; Kee R; MacEwan J; Mucha L; Wong SL; Durand A; Shafrin J
J Med Econ; 2020 May; 23(5):474-483. PubMed ID: 31903813
[No Abstract] [Full Text] [Related]
20. A Study of Patient Preferences for the Treatment of Non-small Cell Lung Cancer in Western China: A Discrete-Choice Experiment.
Liu F; Hu H; Wang J; Chen Y; Hui S; Hu M
Front Public Health; 2021; 9():653450. PubMed ID: 33842426
[No Abstract] [Full Text] [Related]
[Next] [New Search]
